This study contrasts immune checkpoint inhibitor-induced myasthenia gravis (ICI-MG) with idiopathic MG by analyzing AChR autoantibodies. Among three patients with ICI-MG, only one exhibited complement activation and modulation/blocking capabilities akin to idiopathic MG, hinting that AChR autoantibodies may not be pivotal in the disease pathology of the other two. This observation questions the reliability of serological testing as the sole diagnostic tool for ICI-MG and underscores the necessity for thorough clinical evaluations to assess ICI-related adverse events.
